Mercilon Bayer supports contraception (1 blister x 21 tablets)

Dosage form Tablet
Specifications Box of 1 blister x 21 tablets
Ingredient Desogestrel, ethinyletradiol

Ingredient

Thành phần cho 1 viên

Composition information	Content
Desogestrel	0.15mg
Ethinylestradiol	0.02mg

Uses

indications

Mercilon 0.15mg drug is indicated in the following case:

contraceptive.

Pharmacological

Etonogestrel is fully metabolized by known steroid metabolic roads. The rate of clearance from serum transformers is about 2 ml/min/kg. No interaction when used with ethinylestradiol.

Dynamic pharmacokinetics

Desogestrel

absorption:

Desogestrel is used quickly and completely absorbed and is transformed into Etonogestrel. The peak concentration of serum reaches about 1.5 hours. Birth is 62-81%.

Distribution:

Etonogestrel is associated with serum albumin and with globulin bonding sex hormones (SHBG). Only 2-4% of the total serum drug concentration is present in the form of free steroids, 40-70% of specific bond with SHBG. Desogestrel's apparent distribution volume is 1.5 1/kg.

Metabolism:

Etonogestrel is completely metabolized by known steroid metabolism. The rate of clearance from serum transformers is about 2 ml/ min/ kg.

Era:

Etonogestrel concentration in serum decreases into two phases. The last phase has a selling time of about 30 hours. Desogestrel and its metabolites are excreted in urine and in bile in a ratio of about 6: 4.

ethinylestradiol

absorption:

Ethinylestradiol is used quickly and completely absorbed. The peak concentration of serum is reached within 1-2 hours. Absolute bioavailability is about 60%.

Distribution:

Ethinylestradiol is very much but not specific to serum albumin (about 98.5%) and increases SHBG levels in serum. The apparent distribution volume is determined in compartment 5 1/kg.

Metabolism:

EthinyleLestradiol is mainly metabolized by aromatic hydroxylation but forming a metabolic active ingredient and methylation, and these substances are present in the form of free metabolites and associated substances with glucuronides and sulfate. Metabolic clearance speed is about 5 ml/min/kg.

Era:

Ethinylelestradiol levels in serum decrease to two phases, the last phase has a half -time -selling time. The drug is not changed, the metabolites of ethinylelestradiol are excreted in urine and in bile in a ratio of 4: 6. Time to sell metabolic waste about 1 day.

Before taking Mercilon Bayer supports contraception (1 blister x 21 tablets)

How to use

daily take the tablets in the order indicated on the blister of the drug at the same hour with a little water if needed. Take one tablet every day for 21 consecutive days. Start using the next blister after 7 days off.

Dosage

Do not use contraception:

Start taking medicine on the 1st of the natural menstrual cycle (ie the first menstrual day). It is also possible to start drinking on the 2-5 days of the menstrual cycle, but in the first cycle, the method of contraception should be used with a diaphragm for the first 7 days of taking medicine.

Change from another combined contraceptive contraceptive:

It is best to start using Mercise on the day after taking the last tablet with the last active ingredient (the last tablet contains the active ingredient) of the previous coc. But the latest on the next day of the temporary break, or after the last place of Coc's place of the previous place. In the case of using vaginal rings or implants under the skin, it is best to start using Mercise on the day of withdrawing the above tools, but not later than the time should have the next tool.

If the previous method of contraception is used regularly and properly and if it is definitely not pregnant, it can also be exchanged for any day in the cycle of hormone contraceptives in the previous coordination.

From contraception, only progestogen:

Can be exchanged for any day when using a minipill but in all the above cases should use an additional method of the barrier in the first 7 days of taking the drug.

After miscarriage in the first 3 months can start taking the medicine immediately. If drinking like that, there is no need to use additional contraception.

The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose? Symptoms may occur in this case: nausea, vomiting, mild vaginal blood in girls. No antidote and symptomatic treatment only.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Mercilon, you may experience unwanted effects (ADR).

Common, ADR> 1/100:

Mental disorders: Depression, mood change;

Nervous system disorders: headache;

Gastrointestinal disorders: Nausea, abdominal pain;

Testing: weight gain.

Uncommon, 1/1000

Metabolic and nutrition disorders: Keep water;

Mental disorders: Reduce libido;

Gastrointestinal disorders: vomiting, diarrhea;

Skin and subcutaneous tissue disorders: rash, urticaria.

Instructions on how to handle ADR:

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Mercilon drugs contraindicated in the following cases:

There is or a history of venous thrombosis.

Be cautious when using

If there is any of the following risk factors/factors, it is necessary to consider the benefits of using COC with possible risks for all women and discuss with women before they decide to start taking the drug. In the case of severe, dramatic or first -occurred any risk factor, a woman should see a doctor. The doctor will decide whether to stop using coc or not.

circulatory disorders:

Epidemiological studies have shown a combination of COC with increased risk of thrombosis and arterial and vein thrombosis, such as myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism. These events rarely occur.

The use of COC is associated with increased risk of venous thrombosis (VTE) manifests as deep veins and/ or pulmonary embolism. This risk is highest in the first year of using COC. The risk also increases as soon as it starts to use CHC or when starting with the same medicine or another COC after stopping for 4 weeks or more.

The ability to drive and operate machinery

has not observed that it affects the ability to drive and operate machinery.

Pregnancy

do not specify using Mercilon during pregnancy. If you get pregnant during Mercilon, you should stop taking the drug.

The period of breastfeeding

Milk creation can be affected by COC because they reduce the number and change the composition of breast milk. Therefore, COC is often not recommended until the mother has completely weaned for her children. Small amounts of contraceptive steroids and/or their metabolites can be secreted in milk, but there is no evidence that this adversely affects the baby's health.

Interactive drug

Interaction between oral contraceptives and other drugs can cause abnormal blood and/or lose the effect of oral contraceptives. Recorded the following interactions in literature:

Liver metabolism:

Interactions may occur with liver enzyme -induced drugs or herbs, especially cytochrome p450 (CYP) enzymes, leading to increased clearance, reducing plasma concentrations of sex hormones, thus reducing the effectiveness of oral contraceptives, including Mercilon. These drugs include (phenytoin, phenobarbital, primidon, bosentan, carbamazepin, rifampicin, and can be oxcarbazepin, topiramate, felbamate, griseofulvin, some HIV protease inhibitors and non-nucleosid reverse copy inhibitors and st.john's herbal drugs.

When used simultaneously with hormone contraceptives, many combinations of HIV Protease and HIV Protease inhibitors and non-nucleoside reverse copy inhibitors (nevirapine) and/or in combination with anti-hepatitis C (HCV) (for example, BoCeprevir, Telaprevir) can increase or reduce the concentration of progestin in plasma, etON The activity of desogestrel or estrogen.

For women who use long -term enzyme induction drugs, should consider using other contraceptive methods without being affected by enzyme induction drugs. Combining strong CYP 3A4 inhibitors (ketoconazole, otraconazole, clarithromycin) or average (fluconazole, diltiazem, erythromycin) can increase the plasma concentration of estrogen or progestin, including the active transformation of Desogestrel is Etonogestrel.

Oral contraceptives may affect the metabolism of other drugs. Therefore, the concentration of these drugs in plasma and tissue may increase (as with cyclosporin) or decrease (as with lamotrigin).

In clinical trials with the treatment of hepatitis C in combination with ombitasvir/paritaprevir/ritonavir with or without Dasabuvir, the ALT concentration increases more than 5 times higher level (ULN) more common in women using drugs containing ethinylestradiol as CHC.

Storage

Store less than 30 ° C, avoid light and moisture.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.